Delandistrogene moxeparvovec demonstrated a manageable safety profile across clinical trials for Duchenne muscular dystrophy (DMD), with most adverse events emerging within 90 days of infusion. Barry ...
The SportsDay staff is a team of editors and producers on the sports desk who create content for The Dallas Morning News.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback